Skip to main content
MaaT Pharma logo

MaaT Pharma — Investor Relations & Filings

Ticker · MAAT ISIN · FR0012634822 LEI · 969500CQQB6XUNW6CN97 PA Professional, scientific and technical activities
Open in API
Filings indexed 343 across all filing types
Latest filing 2026-05-11 Regulatory Filings
Country FR France
Listing PA MAAT

About MaaT Pharma

https://www.maatpharma.com/

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 90% confidence The document is a press release announcing the convocation and logistical details of the company’s 2026 Annual General Meeting (AGM), together with its forward financial calendar. It does not contain actual AGM materials (presentations or resolutions), nor detailed proxy statements or voting results, and it is not a financial report. Rather, it is a general regulatory announcement to satisfy listing requirements. Therefore it falls under the general Regulatory Filings category (RNS).
2026-05-11 French
Inside Information / Other news releases
Proxy Solicitation & Information Statement Classification · 82% confidence The document is a press release notifying shareholders of the upcoming Annual General Meeting, detailing the convening notice, agenda, draft resolutions, and how to access proxy materials. It is not the AGM presentation itself nor the results, but rather the formal proxy solicitation/information statement sent to shareholders ahead of voting. Therefore, it falls under "Proxy Solicitation & Information Statement (PSI)."
2026-05-11 English
Inside Information / Other news releases
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing the publication of retrospective clinical study data in an academic journal. It contains no financial results, regulatory form filings (such as annual or interim reports), share transactions, management changes, dividends, or other specialized disclosure types. It is not a call transcript or investor presentation. It does not fit any of the specific categories and therefore falls into the general “Regulatory Filings” fallback category.
2026-04-01 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 60% confidence The document is a corporate press release (“Communiqué de presse”) announcing the publication of retrospective clinical data (CHRONOS study) in a peer-reviewed journal. It does not present financial results, regulatory filings for securities, board changes, dividends, or any of the other specific categories provided. This type of broad announcement about study data falls into the general “Regulatory Filings” fallback category (RNS) for miscellaneous corporate announcements that do not fit more narrowly defined report types.
2026-04-01 French
Inside Information / Information on annual revenues
Earnings Release Classification · 89% confidence The document is a press release titled “MaaT Pharma Announces 2025 Annual Results and Provides Business Updates.” It summarizes key financial results (EAP revenues, financing agreements, cash runway, audited results highlights) and operational pipeline progress. It is not the full statutory annual report (10-K) with complete financial statements and notes, nor is it merely an announcement of report publication. Instead, it presents an initial announcement of the company’s full-year results and business developments, consistent with an Earnings Release. Therefore, it aligns with filing type ER. FY 2025
2026-03-31 English
Informations privilégiées / Information sur chiffre d’affaires annuel
Earnings Release Classification · 92% confidence The document is a press release (“Communiqué de presse”) dated March 31, 2026, summarizing MaaT Pharma’s full-year 2025 financial results (EAP revenue, cash position, BEI financing) and key operational and pipeline highlights. It is not a full statutory Annual Report or regulatory form, but a high-level summary release of annual results. This fits the definition of an Earnings Release (ER). FY 2025
2026-03-31 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.